Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 5,074,976 shares, an increase of 19.0% from the October 13th total of 4,264,623 shares. Currently, 7.4% of the shares of the stock are sold short. Based on an average daily volume of 1,355,536 shares, the short-interest ratio is presently 3.7 days.

Separately, ValuEngine upgraded Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 11th.

Ampio Pharmaceuticals (AMPE) traded up $0.01 during midday trading on Monday, reaching $1.16. The company had a trading volume of 288,000 shares, compared to its average volume of 443,702. Ampio Pharmaceuticals has a 1-year low of $0.38 and a 1-year high of $1.34.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals Inc and related companies with's FREE daily email newsletter.